Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $68.20

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $68.20.

A number of analysts have weighed in on the company. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday. KeyCorp assumed coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Barrington Research upped their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the transaction, the chief financial officer now owns 6,452 shares of the company’s stock, valued at $450,091.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $157,182. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 114,036 shares of company stock valued at $7,873,749. 12.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in shares of LeMaitre Vascular by 0.8% during the third quarter. BlackRock Inc. now owns 3,267,883 shares of the medical instruments supplier’s stock valued at $165,616,000 after acquiring an additional 26,787 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 0.5% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock valued at $109,432,000 after acquiring an additional 10,390 shares during the period. Vanguard Group Inc. lifted its stake in LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the period. Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 2.3% in the fourth quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock valued at $71,515,000 after buying an additional 28,720 shares during the period. Finally, Ranger Investment Management L.P. lifted its stake in LeMaitre Vascular by 1.5% in the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after buying an additional 13,681 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 1.0 %

LMAT opened at $63.26 on Wednesday. The stock has a market cap of $1.42 billion, a PE ratio of 47.21, a P/E/G ratio of 2.72 and a beta of 0.87. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $74.64. The stock’s 50 day simple moving average is $65.09 and its 200-day simple moving average is $57.85.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The business had revenue of $48.90 million for the quarter, compared to analysts’ expectations of $49.01 million. During the same period in the previous year, the business posted $0.25 earnings per share. LeMaitre Vascular’s quarterly revenue was up 19.3% on a year-over-year basis. Equities analysts forecast that LeMaitre Vascular will post 1.66 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, March 14th were paid a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, March 13th. This represents a $0.64 dividend on an annualized basis and a yield of 1.01%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s payout ratio is currently 47.76%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.